These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 27680564)

  • 21. Heregulin degradation in the absence of rapid receptor-mediated internalization.
    Baulida J; Carpenter G
    Exp Cell Res; 1997 Apr; 232(1):167-72. PubMed ID: 9141633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.
    Ebbing EA; Medema JP; Damhofer H; Meijer SL; Krishnadath KK; van Berge Henegouwen MI; Bijlsma MF; van Laarhoven HW
    Oncotarget; 2016 Mar; 7(9):10243-54. PubMed ID: 26863569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.
    Landgraf R; Pegram M; Slamon DJ; Eisenberg D
    Biochemistry; 1998 Mar; 37(9):3220-8. PubMed ID: 9485477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma.
    d'Arville CN; Nouri-Aria KT; Johnson P; Williams R
    Hepatology; 1991 Feb; 13(2):310-5. PubMed ID: 1847351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
    Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
    Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
    Pan MH; Lin CC; Lin JK; Chen WJ
    J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer.
    Yonesaka K; Takegawa N; Satoh T; Ueda H; Yoshida T; Takeda M; Shimizu T; Chiba Y; Okamoto I; Nishio K; Tamura T; Nakagawa K
    PLoS One; 2015; 10(11):e0143132. PubMed ID: 26569500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in the antioxidant defense and hepatic drug metabolizing enzyme and isoenzyme levels, 8-hydroxydeoxyguanosine formation and expressions of c-raf.1 and insulin-like growth factor II genes during the stages of development of hepatocellular carcinoma in rats.
    Mukherjee B; Das T; Ghosh S; Datta S
    Eur J Cancer Prev; 2007 Aug; 16(4):363-71. PubMed ID: 17554210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.
    Mirschberger C; Schiller CB; Schräml M; Dimoudis N; Friess T; Gerdes CA; Reiff U; Lifke V; Hoelzlwimmer G; Kolm I; Hopfner KP; Niederfellner G; Bossenmaier B
    Cancer Res; 2013 Aug; 73(16):5183-94. PubMed ID: 23780344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER3 is a determinant for poor prognosis in melanoma.
    Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
    Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
    Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
    EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of butyrate on the heregulin/ErbB-mediated proliferation of human colorectal cancer cells.
    Lim SJ; Choi MK; Kim MJ; Lee CH
    Mol Med Rep; 2009; 2(3):497-502. PubMed ID: 21475856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
    Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
    BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The imprinting status and expression of insulin-like growth factor 2 gene in human hepatocellular carcinoma].
    He WZ; Qin Y; Li B; Liu JY; Sun ZL; Sun ZF
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jul; 35(4):466-9. PubMed ID: 15291100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
    Chen CH; Chernis GA; Hoang VQ; Landgraf R
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9226-31. PubMed ID: 12874383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
    Mazumdar A; Adam L; Boyd D; Kumar R
    Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heregulin and forskolin-induced cyclin D3 expression in Schwann cells: role of a CCAAT promoter element and CCAAT enhancer binding protein.
    Fuentealba L; Schworer C; Schroering A; Rahmatullah M; Carey DJ
    Glia; 2004 Feb; 45(3):238-48. PubMed ID: 14730697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
    Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
    Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.